A Multiple-Center, Open-Label, Study of the Safety and Efficacy of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2009
At a glance
- Drugs IRX 4204 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Sep 2009 New trial record